Ganab Haploinsufficiency Does Not Cause Polycystic Kidney Disease or Polycystic Liver Disease in Mice

Figure 1

Ganab-haploinsufficient mice were constructed via two strategies. (a) Ganab^+/-mouse construction strategies. Strategy I, the designed sgRNA was located in the nonconserved region between intron 4 and intron 10. Strategy II, the designed sgRNA was located in the nonconserved region between intron 5 and intron 17. (b) Screening of sgRNA in targeting vectors, and sgRNA3 and sgRNA9 with higher viability were selected for efficient Ganab gene knockout. (c) Genotyping was performed on randomly selected mice (wild-type and mutant mice) to confirm the absence of the Ganab gene in the mutant mice. Four homozygotes were found in 3.5-day mouse embryos constructed by strategy II. PCR product size for homozygotes: 622 bp/335 bp; heterozygotes: 622 bp/658 bp/335 bp; wild-type allele: 658 bp/335 bp. (d, e) Compared with that in the wild-type group, the GIIa protein expression in the Ganab^+/- group (strategy I) was significantly reduced, and the difference was statistically significant (). Data are presented as the . by 2-tailed test.

(a)

(b)

(c)

(d)

(e)